Related references
Note: Only part of the references are listed.A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients with Duchenne Muscular Dystrophy: Results of the PolarisDMD Trial
Richard S. Finkel et al.
JOURNAL OF NEUROMUSCULAR DISEASES (2021)
Simvastatin Treatment Does Not Ameliorate Muscle Pathophysiology in a Mouse Model for Duchenne Muscular Dystrophy
Ingrid E. C. Verhaart et al.
JOURNAL OF NEUROMUSCULAR DISEASES (2021)
Silencing COX-2 blocks PDK1/TRAF4-induced AKT activation to inhibit fibrogenesis during skeletal muscle atrophy
Hongtao Chen et al.
REDOX BIOLOGY (2021)
ActRIIB:ALK4-Fc alleviates muscle dysfunction and comorbidities in murine models of neuromuscular disorders
Jia Li et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
TGFβ signaling curbs cell fusion and muscle regeneration
Francesco Girardi et al.
NATURE COMMUNICATIONS (2021)
Fibro-adipogenic progenitors in skeletal muscle homeostasis, regeneration and diseases
Thomas Molina et al.
OPEN BIOLOGY (2021)
Oral administration of angiotensin-(1-7) decreases muscle damage and prevents the fibrosis in rats after eccentric exercise
Nadia Lucia Totou et al.
EXPERIMENTAL PHYSIOLOGY (2021)
In vitro assessment of anti-fibrotic drug activity does not predict in vivo efficacy in murine models of Duchenne muscular dystrophy
Marine Theret et al.
LIFE SCIENCES (2021)
Abnormal Calcium Handling in Duchenne Muscular Dystrophy: Mechanisms and Potential Therapies
Satvik Mareedu et al.
FRONTIERS IN PHYSIOLOGY (2021)
Differential Effects of Halofuginone Enantiomers on Muscle Fibrosis and Histopathology in Duchenne Muscular Dystrophy
Sharon Mordechay et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
An anti-ADAMTS1 treatment relieved muscle dysfunction and fibrosis in dystrophic mice
Yan Wang et al.
LIFE SCIENCES (2021)
Anti-latent TGFβ binding protein 4 antibody improves muscle function and reduces muscle fibrosis in muscular dystrophy
Alexis R. Demonbreun et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
The pan HDAC inhibitor Givinostat improves muscle function and histological parameters in two Duchenne muscular dystrophy murine models expressing different haplotypes of the LTBP4 gene
Simonetta Andrea Licandro et al.
SKELETAL MUSCLE (2021)
Mechanisms of statin-associated skeletal muscle-associated symptoms
Jamal Bouitbir et al.
PHARMACOLOGICAL RESEARCH (2020)
Biomarkers for Duchenne muscular dystrophy: myonecrosis, inflammation and oxidative stress
Miranda D. Grounds et al.
DISEASE MODELS & MECHANISMS (2020)
Blocking CTGF/CCN2 reduces established skeletal muscle fibrosis in a rat model of overuse injury
Mary F. Barbe et al.
FASEB JOURNAL (2020)
Early pathological signs in young dysf-/- mice are improved by halofuginone
Hila Barzilai-Tutsch et al.
NEUROMUSCULAR DISORDERS (2020)
Fibrosis: from mechanisms to medicines
Neil C. Henderson et al.
NATURE (2020)
Blocking CCN2 Reduces Progression of Sensorimotor Declines and Fibrosis in a Rat Model of Chronic Repetitive Overuse
Mary F. Barbe et al.
JOURNAL OF ORTHOPAEDIC RESEARCH (2019)
Adult stem cells at work: regenerating skeletal muscle
Manuel Schmidt et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2019)
Fibroadipogenic progenitors are responsible for muscle loss in limb girdle muscular dystrophy 2B
Marshall W. Hogarth et al.
NATURE COMMUNICATIONS (2019)
Angiotensin II receptor blocker losartan exacerbates muscle damage and exhibits weak blood pressure-lowering activity in a dysferlin-null model of Limb-Girdle muscular dystrophy type 2B
Zoe White et al.
PLOS ONE (2019)
The Rebirth of Matrix Metalloproteinase Inhibitors: Moving Beyond the Dogma
Gregg B. Fields
CELLS (2019)
N-acetylcysteine Decreases Fibrosis and Increases Force-Generating Capacity of mdx Diaphragm
David P. Burns et al.
ANTIOXIDANTS (2019)
Regulation and phylogeny of skeletal muscle regeneration
Meryem B. Baghdadi et al.
DEVELOPMENTAL BIOLOGY (2018)
The inhibition of CTGF/CCN2 activity improves muscle and locomotor function in a murine ALS model
David Gonzalez et al.
HUMAN MOLECULAR GENETICS (2018)
Targeting early PKCθ-dependent T-cell infiltration of dystrophic muscle reduces disease severity in a mouse model of muscular dystrophy
Biliana Lozanoska-Ochser et al.
JOURNAL OF PATHOLOGY (2018)
Regulation of fibrosis in muscular dystrophy
Lucas R. Smith et al.
MATRIX BIOLOGY (2018)
Nintedanib decreases muscle fibrosis and improves muscle function in a murine model of dystrophinopathy
Patricia Pinol-Jurado et al.
CELL DEATH & DISEASE (2018)
Nilotinib impairs skeletal myogenesis by increasing myoblast proliferation
Osvaldo Contreras et al.
SKELETAL MUSCLE (2018)
Combined Therapies for Duchenne Muscular Dystrophy to Optimize Treatment Efficacy
Gonzalo Cordova et al.
FRONTIERS IN GENETICS (2018)
Phosphodiesterase 4 inhibitor and phosphodiesterase 5 inhibitor combination therapy has antifibrotic and anti-inflammatory effects in mdx mice with Duchenne muscular dystrophy
Yasunori Nio et al.
FASEB JOURNAL (2017)
Oxidative stress in Duchenne muscular dystrophy: focus on the NRF2 redox pathway
Sara Petrillo et al.
HUMAN MOLECULAR GENETICS (2017)
A Novel NF-κB Inhibitor, Edasalonexent (CAT-1004), in Development as a Disease-Modifying Treatment for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult Subjects
Joanne M. Donovan et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Fibrosis development in early-onset muscular dystrophies: Mechanisms and translational implications
Antonio L. Serrano et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2017)
αv integrins on mesenchymal cells regulate skeletal and cardiac muscle fibrosis
I. R. Murray et al.
NATURE COMMUNICATIONS (2017)
Treatment with the anti-IL-6 receptor antibody attenuates muscular dystrophy via promoting skeletal muscle regeneration in dystrophin-/utrophin-deficient mice
Eiji Wada et al.
SKELETAL MUSCLE (2017)
Pharmacological Inhibition of PKCθ Counteracts Muscle Disease in a Mouse Model of Duchenne Muscular Dystrophy
V. Marrocco et al.
EBIOMEDICINE (2017)
Angiotensin-(1-7) Attenuates Skeletal Muscle Fibrosis and Stiffening in a Mouse Model of Extremity Sarcoma Radiation Therapy
Jeffrey S. Willey et al.
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME (2016)
PDGFRα signalling promotes fibrogenic responses in collagen-producing cells in Duchenne muscular dystrophy
Nicholas Ieronimakis et al.
JOURNAL OF PATHOLOGY (2016)
TGF-β: the master regulator of fibrosis
Xiao-ming Meng et al.
NATURE REVIEWS NEPHROLOGY (2016)
Disease-modifying effects of orally bioavailable NF-κB inhibitors in dystrophin-deficient muscle
David W. Hammers et al.
JCI INSIGHT (2016)
Nilotinib reduces muscle fibrosis in chronic muscle injury by promoting TNF-mediated apoptosis of fibro/adipogenic progenitors
Dario R. Lemos et al.
NATURE MEDICINE (2015)
A new therapeutic effect of simvastatin revealed by functional improvement in muscular dystrophy
Nicholas P. Whitehead et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Sildenafil Does Not Improve Cardiomyopathy in Duchenne/Becker Muscular Dystrophy
Doris G. Leung et al.
ANNALS OF NEUROLOGY (2014)
Restoration of muscle strength in dystrophic muscle by angiotensin-1-7 through inhibition of TGF-β signalling
Maria Jose Acuna et al.
HUMAN MOLECULAR GENETICS (2014)
The profibrotic role of endothelin-1: Is the door still open for the treatment of fibrotic diseases?
Fernando Rodriguez-Pascual et al.
LIFE SCIENCES (2014)
Is there new hope for therapeutic matrix metalloproteinase inhibition?
Roosmarijn E. Vandenbroucke et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Long-term administration of the TNF blocking drug Remicade (cV1q) to mdx mice reduces skeletal and cardiac muscle fibrosis, but negatively impacts cardiac function
N. V. Ermolova et al.
NEUROMUSCULAR DISORDERS (2014)
Tranilast administration reduces fibrosis and improves fatigue resistance in muscles of mdx dystrophic mice
Kristy Swiderski et al.
FIBROGENESIS & TISSUE REPAIR (2014)
LTBP4 genotype predicts age of ambulatory loss in duchenne muscular dystrophy
Kevin M. Flanigan et al.
ANNALS OF NEUROLOGY (2013)
Tyrosine kinase signaling in fibrotic disorders Translation of basic research to human disease
Christian Beyer et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2013)
Inhibition of the angiotensin-converting enzyme decreases skeletal muscle fibrosis in dystrophic mice by a diminution in the expression and activity of connective tissue growth factor (CTGF/CCN-2)
Maria Gabriela Morales et al.
CELL AND TISSUE RESEARCH (2013)
N-Acetylcysteine treatment reduces TNF-α levels and myonecrosis in diaphragm muscle of mdx mice
Rafael de Senzi Moraes Pinto et al.
CLINICAL NUTRITION (2013)
Reducing CTGF/CCN2 slows down mdx muscle dystrophy and improves cell therapy
Maria Gabriela Morales et al.
HUMAN MOLECULAR GENETICS (2013)
Preclinical Studies in the mdx Mouse Model of Duchenne Muscular Dystrophy with the Histone Deacetylase Inhibitor Givinostat
Silvia Consalvi et al.
MOLECULAR MEDICINE (2013)
SURAMIN ATTENUATES DYSTROPHIN-DEFICIENT CARDIOMYOPATHY IN THE mdx MOUSE MODEL OF DUCHENNE MUSCULAR DYSTROPHY
Drielen De Oliveira Moreira et al.
MUSCLE & NERVE (2013)
Angiotensin II-induced pro-fibrotic effects require p38MAPK activity and transforming growth factor beta 1 expression in skeletal muscle cells
Maria Gabriela Morales et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2012)
Angiotensin II receptor type 1 blockade decreases CTGF/CCN2-mediated damage and fibrosis in normal and dystrophic skeletal muscles
Claudio Cabello-Verrugio et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2012)
Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy
Justin M. Percival et al.
JOURNAL OF PATHOLOGY (2012)
Losartan Decreases Cardiac Muscle Fibrosis and Improves Cardiac Function in Dystrophin-Deficient Mdx Mice
Christopher F. Spurney et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2011)
PREVENTION OF MUSCLE FIBROSIS AND MYONECROSIS IN mdx MICE BY SURAMIN, A TGF-beta 1 BLOCKER
Ana Paula Tiemi Taniguti et al.
MUSCLE & NERVE (2011)
Nilotinib: A Novel, Selective Tyrosine Kinase Inhibitor
Jean-Yves Blay et al.
SEMINARS IN ONCOLOGY (2011)
Matrix Metalloproteinase Inhibitor Batimastat Alleviates Pathology and Improves Skeletal Muscle Function in Dystrophin-Deficient mdx Mice
Akhilesh Kumar et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy
Candace M. Adamo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Intramuscular renin-angiotensin system is activated in human muscular dystrophy
Guilian Sun et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2009)
Sarcolemma-localized nNOS is required to maintain activity after mild exercise
Yvonne M. Kobayashi et al.
NATURE (2008)
Prevention of muscle fibrosis and improvement in muscle performance in the mdx mouse by halofuginone
Tidhar Turgeman et al.
NEUROMUSCULAR DISORDERS (2008)
HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment
Claudia Colussi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Protective effects of Ca2+ handling drugs against abnormal Ca2+ homeostasis and cell damage in myopathic skeletal muscle cells
Y Iwata et al.
BIOCHEMICAL PHARMACOLOGY (2005)
Localization and early time course of TGF-β1 mRNA expression in dystrophic muscle
LE Gosselin et al.
MUSCLE & NERVE (2004)
Platelet-derived growth factor and its receptors are related to the progression of human muscular dystrophy: an immunohistochemical study
YJ Zhao et al.
JOURNAL OF PATHOLOGY (2003)
Share Paper
